Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences will host an in-person investor event with a live webcast on October 20, 2026, at 8:30 AM ET in New York City, featuring new casdatifan data in clear cell renal cell carcinoma across first-, second- and late-line settings. The data preview covers 30 patients on casdatifan plus zimberelimab in the first line, roughly 20 on a triple combination with ipilimumab, 43 on casdatifan plus cabozantinib in the second line, and 121 pooled monotherapy patients, with ORR, PFS, OS and the first translational data correlating HIF-2a inhibition markers with overall survival.
Key figures
- Drug Name
- casdatifan (AB521)
- Phase Of Trial
- Phase 3 (PEAK-1 and PEAK-20 registrational trials); ARC-20 platform study
- Peak20 initiation
- expected Q4 2026
- Investor event date
- October 20, 2026
- Peak1 full enrollment
- expected end of 2026
- Patients 1l triple combo
- approximately 20
- Min follow up 2l combo months
- 18
- Median follow up 1l combo months
- approximately 11
- Median follow up 2l combo months
- approximately 21
- Median follow up monotherapy months
- approximately 28
- Patients late line monotherapy pooled
- 121
- Patients 1l casdatifan plus zimberelimab
- 30
- Patients 2l casdatifan plus cabozantinib
- 43
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.